NYSE: STDN
Standard Nuclear, Inc.CIK 0002086716 · SIC 2810 · Industrial Chemicals
No XBRL size data yet — common for recent IPOs and new registrants (SEC companyfacts lag), foreign filers reporting in non-USD, or non-standard filers.
Every 8-K is open in full. Other 10-Ks and 10-Qs show a 3-bullet preview. A free account reads 3 more full reports a month. Generating a report requires a verified account.
Sign up freeWant to see a complete report first? Today's free report (IREN 10-K) is open in full — no account needed.
8-K
Filed Aug 27, 2026
· Period ending Aug 26, 2026
Summary not yet generated.
8-K
Filed Aug 27, 2026
· Period ending Aug 27, 2026
Summary not yet generated.
Partner
Trade STDN commission-free
Open an account, get a free stock.
Investing involves risk. Free stock terms apply.
10-Q
Filed Aug 27, 2026
· Period ending Jun 30, 2026
Summary not yet generated.
8-K
Filed Aug 20, 2026
· Period ending Aug 20, 2026
Summary not yet generated.
8-K
Filed Aug 14, 2026
· Period ending Aug 12, 2026
Summary not yet generated.
8-K
Filed Jul 22, 2026
· Period ending Jul 22, 2026
Summary not yet generated.
8-K
Filed Jul 21, 2026
· Period ending Jul 17, 2026
Summary not yet generated.
424B4
Filed Jul 16, 2026
Summary not yet generated.
S-1/A
Filed Jul 15, 2026
Summary not yet generated.
S-1/A
Filed Jul 7, 2026
Summary not yet generated.
S-1
Filed Jun 18, 2026
Summary not yet generated.
Latest financial statements
From 10-Q filed Aug 27, 2026 (period ending Jun 30, 2026). As printed on the EDGAR/iXBRL face — not generated by the model.
Condensed Consolidated Statements of Operations (Unaudited)
| Description | Three months ended June 30, 2026 | Three months ended June 30, 2025 | Six months ended June 30, 2026 | Six months ended June 30, 2025 |
|---|---|---|---|---|
| Revenue | ||||
| Product Revenue | 3,100,000 | — | 3,101,741 | — |
| Service Revenue | 1,635,791 | 552,939 | 2,227,852 | 930,865 |
| Total Revenue | 4,735,791 | 552,939 | 5,329,593 | 930,865 |
| Cost of Revenue | ||||
| Cost of Revenue | 1,552,797 | 1,182,689 | 6,558,803 | 2,339,637 |
| Total Cost of Revenue | 1,552,797 | 1,182,689 | 6,558,803 | 2,339,637 |
| Gross Profit (Loss) | 3,182,994 | (629,750) | (1,229,210) | (1,408,772) |
| General and administrative costs | 5,520,577 | 1,007,727 | 9,352,625 | 1,642,494 |
| Research and development expenses | 1,957,895 | — | 1,957,895 | — |
| Loss from operations | (4,295,478) | (1,637,477) | (12,539,730) | (3,051,266) |
| Other expense (income): | ||||
| Increase in fair value of SAFE Notes | — | — | — | 7,725,000 |
| Gain on extinguishment of debt | — | — | — | (853,000) |
| Interest income | (877,693) | — | (1,406,994) | — |
| Other expense (income) | — | (9,542) | — | (9,542) |
| Loss before income tax benefit | (3,417,785) | (1,627,935) | (11,132,736) | (9,913,724) |
| Income tax benefit | — | — | — | — |
| Net loss | (3,417,785) | (1,627,935) | (11,132,736) | (9,913,724) |
| Weighted average common shares outstanding basic and diluted | 28,001,802 | 28,000,000 | 28,000,906 | 28,000,000 |
| Basic and diluted net loss per share | (0.12) | (0.06) | (0.40) | (0.35) |
Condensed Consolidated Balance Sheets (Unaudited)
| Description | June 30, 2026 | December 31, 2025 |
|---|---|---|
| ASSETS | ||
| CURRENT ASSETS: | ||
| Cash and cash equivalents | 102,185,333 | 63,101,704 |
| Accounts receivable and contract assets, net | 8,128,817 | 2,291,669 |
| Deferred transaction costs | 2,135,079 | — |
| Prepaid and other current assets | 646,981 | — |
| Total current assets | 113,096,210 | 65,393,373 |
| Property and equipment, net | 31,375,038 | 12,627,624 |
| Investment in Joint Venture | 2,481,829 | 1,130,170 |
| TOTAL ASSETS | 146,953,077 | 79,151,167 |
| LIABILITIES, MEZZANINE EQUITY, AND STOCKHOLDERS’ DEFICIT | ||
| CURRENT LIABILITIES: | ||
| Accounts payable | 4,567,617 | 2,082,547 |
| Accrued and other liabilities | 148,148 | 354,601 |
| Deferred revenue | 4,031,783 | 1,076,531 |
| Total current liabilities | 8,747,548 | 3,513,679 |
| Asset retirement obligations | 795,254 | 753,223 |
| TOTAL LIABILITIES | 9,542,802 | 4,266,902 |
| Commitments and contingencies | ||
| Mezzanine equity: | ||
| Redeemable preferred stock, 116,141,488 shares authorized, issued and outstanding at June 30, 2026 and 101,948,458 shares authorized, issued and outstanding at December 31, 2025; redemption value $214,999,997 and $144,999,977 at June 30, 2026 and December 31, 2025, respectively (1) | 214,999,997 | 144,999,977 |
| Stockholders’ Deficit: | ||
| Ordinary shares, $0.00001 par value; 0 shares authorized, issued and outstanding at June 30, 2026 and December 31, 2025 | — | — |
| Class A Common Stock, $0.00001 par value; 175,000,000 shares authorized at June 30, 2026 and December 31, 2025; 14,504,000 shares issued and outstanding at June 30, 2026 and December 31, 2025 (1) | 145 | 145 |
| Class B Convertible Common Stock, $0.00001 par value; 35,615,000 shares authorized at June 30, 2026 and December 31, 2025; 13,630,998 shares and 13,496,000 shares issued and outstanding at June 30, 2026 and December 31, 2025, respectively (1) | 135 | 135 |
| Additional paid-in capital | 5,680,085 | 2,021,359 |
| Accumulated deficit | (83,270,087) | (72,137,351) |
| Total Stockholders’ Deficit | (77,589,722) | (70,115,712) |
| Total Liabilities, Mezzanine Equity, and Stockholders’ Deficit | 146,953,077 | 79,151,167 |
Condensed Consolidated Statements of Cash Flows (Unaudited)
| Description | Six months ended June 30, 2026 | Six months ended June 30, 2025 |
|---|---|---|
| Net loss | (11,132,736) | (9,913,724) |
| Adjustments to reconcile net loss to net cash flows from operating activities: | ||
| Share-based compensation expense | 3,657,502 | 175,702 |
| Depreciation expense | 598,881 | 58,292 |
| Change in fair value of SAFE Notes liability | — | 7,725,000 |
| Gain on extinguishment of SAFE Notes | — | (853,000) |
| Changes in operating assets and liabilities: | ||
| Accounts receivable and contract assets, net | (5,837,148) | (312,810) |
| Prepaid and other current assets | (646,981) | (31,250) |
| Accounts payable | (367,886) | 298,994 |
| Accrued expenses and other liabilities | (164,420) | 66,516 |
| Deferred revenue | 2,955,252 | 27,212 |
| Net cash used in operating activities | (10,937,536) | (2,759,068) |
| Cash flows from investing activities | ||
| Purchases of property and equipment | (17,419,069) | (554,743) |
| Contributions to equity method investment | (425,931) | — |
| Net cash used in investing activities | (17,845,000) | (554,743) |
| Cash flows from financing activities | ||
| Proceeds from issuance of convertible redeemable preferred shares | 70,000,020 | — |
| Exercise of stock options | 1,224 | — |
| Payment of deferred transaction costs | (2,135,079) | |
| Proceeds from issuance of Series Seed preferred stock, net of issuance costs | — | 7,945,686 |
| Net cash provided by financing activities | 67,866,165 | 7,945,686 |
| Net increase in cash and cash equivalents | 39,083,629 | 4,631,875 |
| Cash and cash equivalents at beginning of period | 63,101,704 | 1,619,817 |
| Cash and cash equivalents at end of period | 102,185,333 | 6,251,692 |
| Supplemental disclosure of cash flow information: | ||
| Cash paid for interest | — | — |
| Cash paid for income taxes | — | — |
| Supplemental disclosure of non-cash investing and financing activities: | ||
| Conversion of SAFE Notes into Series Seed-1 Preferred stock | — | 32,500,000 |
| Reclassification of SAFE Notes fair value to mezzanine equity upon conversion | — | 32,500,000 |
| Extinguishment of SAFE Notes (reduction of SAFE liability) | — | 1,000,000 |
| Reclassification of short-term cash advances to Series Seed preferred stock | — | 2,494,833 |
| Investment in joint venture included in accounts payable | 925,729 | — |
| Property and equipment purchases included in accounts payable | 1,927,226 | 44,406 |
Amounts as printed on the EDGAR/iXBRL face. Labels, columns, and figures are the filing face, not a GAAP stencil. Interactive statements & notes on EDGAR ↗